Addition of a Pectoserratus Block to Interscalene Block in Patients Undergoing Total Shoulder Replacement

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-85
SponsorUniversity of Minnesota

About this trial

The use of ISB in patients undergoing total shoulder arthroplasty (TSA) is the gold standard and results in significantly reduced pain scores and opioid use. However, patients still have pain and the majority require opioids postoperatively as the interscalene block (ISB) doesn't cover all of the dermatomes impacted during TSA. A pectoserratus block typically provides coverage to additional dermatomes that are impacted during TSA. Currently ISB is performed for every patient and perform a pectoserratus block to a portion of our patients undergoing TSA. The purpose of the study is to determine if the addition of the pectoserratus block to the ISB will results in improvement in pain control and decrease in opioid use, among patients undergoing TSA. This is a randomized prospective controlled trial. All patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty aged 18-85 will be considered eligible for the study. Participants will be randomized to one of 2 treatment groups. Group 1 will receive an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine. Group 2 will be the control and receive an ultrasound guided pectoserratus block with 25 mL of saline. The drug will be administered by the anesthesiologist in-charge of the participant's care or an anesthesiologist who is a part of the study team.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients undergoing total shoulder arthroplasty or reverse total shoulder arthroplasty;

Patients aged 18-85 years old.

Disqualifiers

Patients who have an exclusion to regional anesthesia such as pre-existing nerve damage to their brachial plexus or infection at the site of injection.

Patients who have exclusion to interscalene blockade such as severe lung disease.

Non-English speakers will be excluded because pain scales are not validated in other languages and there is lack of standardization of pain reporting.

Pregnant patients

Trial design

Design model

Parallel

Treatments tested in this trial

  • bupivacaine.

    Drug

    an ultrasound guided pectoserratus block with 25 mL of 0.25% bupivacaine

  • Saline

    Drug

    an ultrasound guided pectoserratus block with 25 mL of saline

Treatment groups

110 Participants
are divided into 2 treatment groups
Group A: Bupivacaine groupExperimental treatment 1 intervention
Group B: control groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Maximum pain

This measurement is the highest pain score within the first 24 hours post-op. Please change abbreviations for time frames to minutes, hours and years respectively. And the Scale is 0 being no pain to 10 being worst pain.

Time frame
24 hours postop

Secondary outcomes

1

Opioid use

Opioid use reported as MME

Time frame
24 hours postop, 48 hours postop
2

Functional pain score

The scale used in a modified QOR (quality of Recovery) scale. It's 15 questions based off the adult QOR scale which assesses impact of pain on the patient's daily activities

Time frame
24 hours postop, 48hours postop
3

hospital length of stay

This is a standard post-operative outcome that relates to the surgical recovery period. Idon't know what options you have to select for time frame, but please either select post-op or explain this standard.

Time frame
5 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.